Loading clinical trials...

Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori

NCT02776371•Shandong University

View on ClinicalTrials.gov

Summary

Helicobacter pylori (H. pylori) infects more than 50% of the population in the world(1), especially 47-66% in China.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Patients who were intend to undergo upper endoscopy for any purpose and volunteered to written inform consent.

Exclusion Criteria

•negative in rapid urease test (RUT)
•previous standard eradication therapy for H. pylori;
•history of esophagectomy or gastrectomy;
•gastrointestinal malignancy;
•contraindications or allergic to study drugs;
•user of taking medicine that may affect the result of the study within 4 weeks (e.g., proton-pump inhibitors, H2-receptor antagonists, bismuth or antibiotics etc.);
•cardiopulmonary, hepatic or renal insufficiency, and/or severe current diseases or malignancy;
•pregnant or lactating women;
•participants of other trial within the past 3 months;
•unwilling or unable to participate in the study.

Locations (1)

Department of Gastroenterology, Qilu Hospital, Shandong University

Jinan, Shandong, China

Key Dates

Start Date

September 1, 2016

Primary Completion Date

January 1, 2018

Completion Date

February 1, 2018

Last Updated

December 24, 2018

Enrollment

301

ACTUAL participants

Conditions

Helicobacter Pylori Eradication Rate

Interventions

Modified non-clarithromycin triple therapy

DRUG

Sequential therapy

DRUG

Efficacy of Short-message-based Re-education (SMRE) on Helicobacter Pylori Eradication

NCT02833623

Helicobacter Pylori Eradication Rate

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 24, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions